Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma

British Journal of Haematology

Volumn 117, Issue 4, 2002, Pages 882-885

  Sahara, Naohi ^a,b   Takeshita, Akihiro ^a,b   Shigeno, Kazuyuki ^a   Fujisawa, Shinya ^a   Takeshita, Kaori ^a   Naito, Kensuke ^a   Ihara, Michio ^c   Ono, Takaaki ^c   Tamashima, Sadahiro ^c   Nara, Kenji ^d   Ohnishi, Kazunori ^a   Ohno, Ryuzo ^e  

^a Internal Medicine III   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

^d Seirei Mikatabara General Hospital   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

CD56; Flow cytometry; Multiple myeloma; Plasmablast; Prognosis

Indexed keywords

BENCE JONES PROTEIN; BETA 2 MICROGLOBULIN; CD56 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CELL MATURATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MULTIPLE MYELOMA; PATHOLOGY; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; STRUCTURE ANALYSIS; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; BENCE JONES PROTEIN; BETA 2-MICROGLOBULIN; BONE MARROW CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; PROGNOSIS; SURVIVAL RATE;

EID: 0036284128     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03513.x     Document Type: Article

References (9)

1. Staging and kinetics of multiple myeloma
2. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
3. Multiple myeloma: Significance of plasmablastic subtype in morphological classification
4. Plasmablastic morphology - An independent prognostic factor with clinical and laboratory correlates: Eastern cooperative oncology group (ECOG) myeloma trial E9486 report by the ECOG myeloma laboratory group
5. Phenotypic difference of normal plasma cells from mature myeloma cells
6. Clinicopathological correlates of CD56 expression in multiple myeloma: A unique entity?
7. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma
8. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression
9. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: Cd56 (NKH-1; Leu-19)